Fulcrum Therapeutics, Inc. - FULC EV/Sales Multiple

Public company logo of fulcrumtx.com (FULC)

The complexity of the careful delivery of drugs for rare pathologies impacts the stock dynamics of Fulcrum Therapeutics (FULC), as evidenced by the change in EV/Sales. The current value of this metric is 0.00. The growth in the value of Fulcrum Therapeutics (FULC) relies on the development of FSHD therapy and M&A potential. The stability of the patient database in anemia trials is currently strictly regulated by FDA quotas.

Fulcrum Therapeutics - FULC Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/20/2026)

Fulcrum Therapeutics, Inc. - analytical breakdowns and key metrics (FULC)

- money and cash flow information:
Fundamental valuation:FULC - fulcrumtx.com
Mass-produced product of fulcrumtx.com

The EV/Sales ratio reflects the enterprise value of the business, net of debt, relative to sales volume. Investors utilize this multiple to assess revenue capitalization efficiency without distortions from the financing structure. By analyzing the trend of enterprise value to revenue, one can identify hidden growth deceleration or asset overvaluation. For Fulcrum Therapeutics (FULC), such a metric confirms the market's bet on the success of joint developments with academic institutions. The valuation of the efficiency of bringing genetic drugs to market directly impacts the stability of this indicator.